A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants

Healthy Clinical Trial

Official title:

Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled RO7034067 in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03036501
• Other study ID #: BP39122
• Secondary ID: 2016-003461-26
• Status: Completed
• Phase: Phase 1
• Start date: January 3, 2017
• Est. completion date: February 28, 2017

Study information

• Verified date: October 2018
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-randomized study investigating the excretion balance, PK and metabolism of a single oral dose of [14C]-labeled Risdiplam (RO7034067) in healthy male participants. This study will assess the characterize mass balance, routes and rates of elimination of [14C]-labeled Risdiplam (RO7034067), using conventional analytical methods and assess the pharmacokinetics of total drug related [14C]-radioactivity, Risdiplam (RO7034067) and its metabolite(s).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: February 28, 2017
• Est. primary completion date: February 28, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy male participants, 35 to 65 years of age (inclusive)

• A body mass index between 18 to 30 kg/m^2 inclusive

• Agreement to use two methods of contraception, during the treatment period and for at least 4 months after the last dose of study drug. One of the contraceptive methods must be a condom. The second contraceptive method must include one of the following: diaphragm or cervical cap, intra-uterine device or system, or oral, injected or implanted hormonal method of contraception.

• No intention of donating sperm within 4 months of study drug administration

• Able to participate and willing to give written informed consent and to comply with the study requirements and restrictions

• Fluent in the language of the Investigator and study staff and able to communicate with the study staff

Exclusion Criteria:

• Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk or interfere with the ability of the participant to complete the study in the opinion of the Investigator

• History of any clinically significant gastrointestinal, renal, hepatic, broncho- pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, hypofertility, cancer or cirrhosis

• Participants with any clinically significant eye pathology affecting best-corrected visual acuity, or optic neuritis retinal abnormalities on spectral domain - optical coherence tomography and 7-field fundus color photography as assessed by an ophthalmologist

• History or evidence of (neuro) muscular disorders

• History or evidence of any medical condition potentially altering the absorption, metabolism or elimination of drugs. Surgical history of the gastrointestinal tract affecting gastric motility or altering the gastrointestinal tract

• History or evidence of skin disorders, as assessed by a thorough skin examination of the whole body

• History of malignancy in the past 5 years

• A history of clinically significant hypersensitivity (e.g., drugs, excipients) or allergic reactions

• Participants who, in the Investigator's judgment, pose a suicidal or homicidal risk, or any participant with a history of suicidal or homicidal attempts

• Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to study drug administration

• History or presence of clinically significant ECG abnormalities before study drug administration or cardiovascular disease

• Clinically significant abnormalities in laboratory test results

• Positive results on tests for human immunodeficiency virus (HIV)-1 or HIV-2, hepatitis C virus or hepatitis B virus

• Any suspicion or history of alcohol abuse and/or suspicion of regular consumption of drugs of abuse

• Confirmed systolic blood pressure (SBP) greater than 150 or less than 90 mmHg, and diastolic blood pressure (DBP) greater than 95 or less than 50 mmHg

• Confirmed (based on the average of at least 3 consecutive measurements) resting pulse rate greater than 100 or less than 40 bpm

• Participation in an investigational drug or device study within 90 days prior to screening, as calculated from the day of follow-up from the previous study

• Smokers who regularly smoke more than 10 cigarettes daily or equivalent tobacco- containing products

• Dietary restrictions that would prohibit the consumption of standardized meals

• Use of any prohibited medications and food before study start and during the study

• Participants under judicial supervision, guardianship or curatorship

• Infrequent bowel movements (less than once per 24 hours on average)

• Regular work with ionizing radiation or radioactive material

• Participants who plan to attempt to father children within 4 months after study drug administration

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• [^14C]-Risdiplam
[^14C]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries [µCi]) of [14C]-labeled Risdiplam.

Locations

Country	Name	City	State
Netherlands	Pra International Group B.V	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Dose Recovered as Total [14C]-radioactivity in Urine		Day 1 to Day 36
Primary	Cumulative Urinary Amount of Total [14C]-Radioactivity in Urine		Day 1 to Day 36
Primary	Percentage of Dose Recovered as Total [14C]-radioactivity in Feces		Day 1 to Day 36
Primary	Maximum Observed Plasma Concentration (Cmax) of Risdiplam		Day 1 to Day 36
Primary	Time to Maximum Observed Plasma Concentration of Risdiplam (Tmax)		Day 1 to Day 36
Primary	Area Under the Plasma Concentration-time Curve from Time 0 to Last Measurable Concentration Time Point (AUC0-last)		Day 1 to Day 36
Primary	Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)		Day 1 to Day 36
Primary	Apparent Terminal Elimination Half-Life (t1/2)		Day 1 to Day 36
Secondary	Percentage of Participants with Adverse Events		Up to 10 weeks
Secondary	Percentage of Participants with Laboratory, ECGs, Ophthalmological Assessments, And Vital Signs Abnormalities		Up to 10 weeks